<DOC>
	<DOCNO>NCT01845623</DOCNO>
	<brief_summary>This study ass pharmacodynamics , safety , tolerability pharmacokinetics indacaterol maleate ( QAB149 ) , administer via EPIC test fixture . The study aim determine whether novel device similar clinical profile establish concept 1 device .</brief_summary>
	<brief_title>A Study Evaluate Effects Indacaterol Maleate ( QAB149 ) New Formulation EPIC Test Fixture</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female patient asthma , age 18 Patients use inhale corticosteroid ( without long act beta agonist ) Patients demonstrate increase FEV1 inhale short act beta agonist Asthma exacerbations previous 6 month COPD pulmonary disease Excessive use short act beta agonist Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>QAB149</keyword>
</DOC>